In a free society, individuals should be free to care for their physical well-being as they see fit, which includes the freedom to choose the medical treatments they think best. Such liberty does not open the door for fraud or abuse any more than does a free market in other products. In fact, informed consent by patients will become more sophisticated as the market for information about medical treatments becomes more free and open.

More on FDA and Drug Regulation

Commentary

The Case to Reclassify Grass

By Jeffrey Miron. Newsweek. March 10, 2015.

Eric Garner Could Spark American Spring

By David Boaz. USA Today. December 5, 2014.

The Genetics Revolution Challenge and How to Incentivize Biomedical Research

By Arnold Kling. The American. June 30, 2014.

Cato Studies

Avoiding Medicare’s Pharmaceutical Trap

By Doug Bandow. Policy Analysis No. 556. November 30, 2005.

Treating Doctors as Drug Dealers: The DEA’s War on Prescription Painkillers

By Ronald T. Libby. Policy Analysis No. 545. June 6, 2005.

Health Care Regulation: A $169 Billion Hidden Tax

By Christopher J. Conover. Policy Analysis No. 527. October 4, 2004.

Public Filings

New York v. Actavis plc

By Ilya Shapiro. Legal Briefs. January 15, 2015.

Ter Beek v. City of Wyoming

By Robert Mikos. Legal Briefs. August 20, 2013.

IMS Health v. Sorrell

By Ilya Shapiro. Legal Briefs. July 14, 2009.

Cato Reviews & Journals

Concerns about Federal GMO Food Legislation

Henry I. Miller and Drew L. Kershen. Regulation. Spring 2015.

Still Awaiting the ‘Biosimilars’ Revolution

Henry I. Miller. Regulation. Spring 2015.

Mandatory Food Labeling for GMOs

Thomas A. Hemphill and Syagnik Banerjee. Regulation. Winter 2014-2015.

Events

The Kidney Sellers: A Journey of Discovery in Iran

Featuring Michael D. Tanner. March 26, 2014. Book Forum.

Drug Reimportation: The Free-Market Solution

Featuring . September 20, 2004. Capitol Hill Briefing.

Resolved: Congress Should Remove the Ban on Drug Reimportation

Featuring Roger Pilon. March 30, 2004. Policy Forum.